Crescent Biopharma (CBIO) Non-Current Deffered Revenue (2013 - 2018)
Crescent Biopharma (CBIO) reported Non-Current Deffered Revenue of $611623.0 for Q4 2018, down 13.49% year-over-year from $707003.0 in Q4 2017, and down 4.39% on a QoQ basis from $639733.0 in Q3 2018.
Crescent Biopharma (CBIO) has 6 years of Non-Current Deffered Revenue data on file, last reported at $611623.0 in Q4 2018.
- Quarterly Non-Current Deffered Revenue fell 13.49% year-over-year to $611623.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $611623.0 (down 13.49% YoY) and the FY2018 annual result came in at $611623.0, down 13.49% from the prior year.
- Non-Current Deffered Revenue fell to $611623.0 in Q4 2018 per CBIO's latest filing, from $639733.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $841426.0 in Q3 2016 and bottomed at $9709.0 in Q3 2014.
- The 5-year median for Non-Current Deffered Revenue is $639733.0 (2018), against an average of $473283.4.
- The widest annual swing landed in 2015, when Non-Current Deffered Revenue retreated 27.5%; it then soared 2739.56% in 2016.
- Tracing CBIO's Non-Current Deffered Revenue over 5 years: stood at $97012.0 in 2014, then jumped by 151.15% to $243647.0 in 2015, then soared by 209.29% to $753579.0 in 2016, then retreated by 6.18% to $707003.0 in 2017, then retreated by 13.49% to $611623.0 in 2018.
- Per Business Quant, the three latest CBIO Non-Current Deffered Revenue figures stand at $611623.0 (Q4 2018), $639733.0 (Q3 2018), and $663745.0 (Q2 2018).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 611,623.00 |
| Sep 30, 2018 | 639,733.00 |
| Jun 30, 2018 | 663,745.00 |
| Mar 31, 2018 | 685,689.00 |
| Dec 31, 2017 | 707,003.00 |
| Sep 30, 2017 | 801,058.00 |
| Jun 30, 2017 | 742,584.00 |
| Mar 31, 2017 | 824,653.00 |
| Dec 31, 2016 | 753,579.00 |
| Sep 30, 2016 | 841,426.00 |
| Jun 30, 2016 | 799,478.00 |
| Mar 31, 2016 | 250,143.00 |
| Dec 31, 2015 | 243,647.00 |
| Sep 30, 2015 | 186,526.00 |
| Jun 30, 2015 | 28,155.00 |
| Dec 31, 2014 | 97,012.00 |
| Sep 30, 2014 | 9,709.00 |
| Jun 30, 2014 | 38,837.00 |
| Mar 31, 2014 | 67,785.00 |
| Dec 31, 2013 | 96,756.00 |